Chemotherapy News and Research

Latest Chemotherapy News and Research

Parents administering highly complex medication regimens require additional supports

Parents of children with chronic conditions make many mistakes when giving lifesaving medicines, according to a study being presented Monday, May 3 at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.

3 May 2010

BSGI improves breast cancer detection

A new study, presented at the American Society of Breast Surgeons Annual Meeting in Las Vegas, found that Breast-Specific Gamma Imaging (BSGI) is highly accurate in monitoring the response of breast cancers to neoadjuvant chemotherapy.

3 May 2010

FDA oks 'vaccine' to treat prostate cancer

Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.

3 May 2010

Study indicates older women with diabetes have increase risk for colon cancer

A research team led by Mayo Clinic physicians has found that older women with diabetes face a more than doubled risk for some types of colorectal cancer.

3 May 2010

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced non-small cell lung cancer.

3 May 2010

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Tikcro Technologies Ltd. today announced that BioCancell Therapeutics, Inc., concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to conventional treatment.

3 May 2010

Accelerated radiotherapy improves overall survival of patient with NSCLC: Report

A new meta-analysis reported at the second European Lung Cancer Conference shows that patients with both non-small-cell lung cancer and small-cell lung cancer benefit in terms of overall survival when treated with hyperfractionated or accelerated radiotherapy.

30 Apr 2010

Registration for 2010 Siemens Competition in Math, Science & Technology opens

Starting today, aspiring scientists and mathematicians nationwide can register for the 2010 Siemens Competition in Math, Science & Technology, the premiere original research competition for high school students in the United States. In just six months, submitted projects will be judged and the countdown to the national finals in Washington, D.C. will begin.

30 Apr 2010

Computers may cause physical problems to children: Researchers

Professor Straker said the guidelines were important because computer use by children was extremely high globally and discomfort reported by children using computers was increasing.

30 Apr 2010

ADVENTRX reports first-quarter net loss applicable to common stock of $4.9 million

ADVENTRX Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2010.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

Study confirms MammaPrint's capabilities in determining patients likely to benefit from chemotherapy

Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test. The ASBS meeting takes places April 28 - May 2, 2010, at the Bellagio in Las Vegas, where you can meet the Agendia team at booth # 314.

30 Apr 2010

PROVENGE receives FDA approval for treatment of CRPC

Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

30 Apr 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

Women with family history of breast cancer face increase risk of ovarian cancer

Ovarian cancer is the most deadly disease of the female reproductive system, with most cases diagnosed in later stages. Yet while ovarian cancer affects 1 in 70 women in the United States, many women have never discussed the risk with their doctor.

30 Apr 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 fiscal year (3QFY10).

30 Apr 2010

FDA approves Provenge prostate cancer vaccine

Cancer may now be fought with a vaccine. The FDA has finally approved an immune boosting vaccine which is said to extend survival of patients at an advanced stage of prostate cancer by four months. This is twice as long as what could be expected with regular chemotherapy. There is also an increase of three years survival after detection in initial stage by 38% thanks to the vaccine.

30 Apr 2010

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

Bavarian Nordic A/S announced today that PROSTVAC™ has been granted Fast Track designation by the U.S. Food & Drug Administration (FDA) for its proposed use in the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

29 Apr 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

29 Apr 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

29 Apr 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Parents administering highly complex medication regimens require additional supports

BSGI improves breast cancer detection

FDA oks 'vaccine' to treat prostate cancer

Study indicates older women with diabetes have increase risk for colon cancer

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Accelerated radiotherapy improves overall survival of patient with NSCLC: Report

Registration for 2010 Siemens Competition in Math, Science & Technology opens

Computers may cause physical problems to children: Researchers

ADVENTRX reports first-quarter net loss applicable to common stock of $4.9 million

REGN reports net loss of $30.5M for first-quarter 2010

Study confirms MammaPrint's capabilities in determining patients likely to benefit from chemotherapy

PROVENGE receives FDA approval for treatment of CRPC

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

Women with family history of breast cancer face increase risk of ovarian cancer

Immunogen reports a net loss of $12.1 million in third quarter 2010

FDA approves Provenge prostate cancer vaccine

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in